Zenitar's  Patient-Derived Organoid Xenograft (PDOX) Screening Platform offers a powerful and clinically relevant tool for cancer research and drug development. By transplanting patient-derived tumors into the corresponding organ sites of immunodeficient mice, this platform accurately replicates the tumor microenvironment, enabling studies on tumor behavior, metastasis, and drug resistance. It significantly enhances the predictive accuracy for personalized drug screening. In the future, with the potential for a humanized immune microenvironment, the PDOX model can be used to study immunotherapy interactions, serving as an essential platform for developing new therapeutic strategies closely aligned with clinical needs.